WallStSmart

Akso Health Group ADR (AHG)vsNorthrop Grumman Corporation (NOC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Northrop Grumman Corporation generates 285348% more annual revenue ($42.37B vs $14.84M). NOC leads profitability with a 10.8% profit margin vs 0.0%. NOC earns a higher WallStSmart Score of 63/100 (C+).

AHG

Avoid

16

out of 100

Grade: F

Growth: 6.0Profit: 2.5Value: 6.0Quality: 7.5
Piotroski: 2/9Altman Z: 7.29

NOC

Buy

63

out of 100

Grade: C+

Growth: 6.0Profit: 7.0Value: 4.0Quality: 4.5
Piotroski: 3/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AHGUndervalued (+19.4%)

Margin of Safety

+19.4%

Fair Value

$1.75

Current Price

$1.98

$0.23 discount

UndervaluedFair: $1.75Overvalued
NOCSignificantly Overvalued (-60.6%)

Margin of Safety

-60.6%

Fair Value

$422.70

Current Price

$549.52

$126.82 premium

UndervaluedFair: $422.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AHG2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
7.2910/10

Safe zone — low bankruptcy risk

NOC4 strengths · Avg: 9.0/10
EPS GrowthGrowth
84.9%10/10

Earnings expanding 84.9% YoY

Market CapQuality
$78.44B9/10

Large-cap with strong market position

Return on EquityProfitability
28.5%9/10

Every $100 of equity generates 29 in profit

P/E RatioValuation
17.3x8/10

Attractively priced relative to earnings

Areas to Watch

AHG4 concerns · Avg: 3.8/10
Price/BookValuation
8.6x4/10

Trading at 8.6x book value

Revenue GrowthGrowth
0.9%4/10

0.9% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.76B3/10

Smaller company, higher risk/reward

NOC4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : AHG

The strongest argument for AHG centers on Debt/Equity, Altman Z-Score.

Bull Case : NOC

The strongest argument for NOC centers on EPS Growth, Market Cap, Return on Equity.

Bear Case : AHG

The primary concerns for AHG are Price/Book, Revenue Growth, EPS Growth.

Bear Case : NOC

The primary concerns for NOC are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

NOC carries more volatility with a beta of -0.11 — expect wider price swings.

NOC is growing revenue faster at 4.4% — sustainability is the question.

AHG generates stronger free cash flow (3M), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NOC scores higher overall (63/100 vs 16/100). AHG offers better value entry with a 19.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Akso Health Group ADR

HEALTHCARE · MEDICAL DISTRIBUTION · China

Akso Health Group ADR is a leading entity in the healthcare sector, focused on delivering innovative medical solutions and comprehensive patient care services. The company utilizes advanced health technologies to exploit burgeoning opportunities in telehealth and personalized medicine, supported by a strong emphasis on research and development. With a solid business model and a highly proficient workforce, Akso Health Group represents a compelling investment opportunity for institutional investors looking to capitalize on the dynamic changes within the healthcare industry.

Visit Website →

Northrop Grumman Corporation

INDUSTRIALS · AEROSPACE & DEFENSE · USA

Northrop Grumman Corporation (NYSE: NOC) is an American multinational aerospace and defense technology company.

Visit Website →

Want to dig deeper into these stocks?